1-6 of 6
Jifeng Feng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Tao Jiang, Qiqi Jin, Jiahao Wang, Fengying Wu, Jian Chen, Gongyan Chen, Yunchao Huang, Jianhua Chen, Ying Cheng, QiMing Wang, Yueyin Pan, Jianying Zhou, Jianhua Shi, Xingxiang Xu, LiZhu Lin, Wei Zhang, Yiping Zhang, Yunpeng Liu, Yong Fang, Jifeng Feng, Zhehai Wang, Sheng Hu, Jian Fang, Yongqian Shu, Jiuwei Cui, Yi Hu, Wenxiu Yao, Xingya Li, Xiaoyan Lin, Rui Wang, Yongsheng Wang, Wei Shi, Gaohua Feng, Jun Ni, Beibei Mao, Dandan Ren, Huaibo Sun, Henghui Zhang, Luonan Chen, Caicun Zhou, Shengxiang Ren
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4830–4843.
https://doi.org/10.1158/1078-0432.CCR-23-0604
Published: 01 December 2023
View article titled, HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer
Open the PDF for HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study

Jifeng Feng, Dihong Tang, Jing Wang, Qi Zhou, Jin Peng, Hanmei Lou, Yuping Sun, Yunlang Cai, Hongmin Chen, Junqin Yang, Pan Liu, Linna Wang, Jianjun Zou
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5297–5305.
https://doi.org/10.1158/1078-0432.CCR-22-0346
Published: 15 December 2022
View article titled, SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study
Open the PDF for SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study in another window
Includes: Supplementary data
Journal Articles

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study

Qing Zhou, Lin Wu, Pei Hu, Tongtong An, Jianying Zhou, Li Zhang, Xiao-Qing Liu, Feng Luo, Xin Zheng, Ying Cheng, Nong Yang, Junling Li, Jifeng Feng, Baohui Han, Yong Song, Kai Wang, Li Zhang, Jian Fang, Hong Zhao, Yongqian Shu, Xiao-Yan Lin, Zhihong Chen, Bin Gan, Wan-Hong Xu, Wei Tang, Xiaoying Zhang, Jin-Ji Yang, Xiao Xu, Yi-Long Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1127–1135.
https://doi.org/10.1158/1078-0432.CCR-21-2595
Published: 15 March 2022
View article titled, A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
Open the PDF for A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study in another window
Includes: Supplementary data
Journal Articles

Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy

Caicun Zhou, Yina Wang, Jun Zhao, Gongyan Chen, Zhihua Liu, Kangsheng Gu, Meijuan Huang, Jianxing He, Jianhua Chen, Zhiyong Ma, Jifeng Feng, Jianhua Shi, Xinmin Yu, Ying Cheng, Yu Yao, Yuan Chen, Renhua Guo, Xiaoyan Lin, Zhehai Wang, Guanghui Gao, Quanren Wang, Weixia Li, Xinfeng Yang, Lihong Wu, Jun Zhang, Shengxiang Ren
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1296–1304.
https://doi.org/10.1158/1078-0432.CCR-20-3136
Published: 01 March 2021
View article titled, Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy
Open the PDF for Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study

Ligang Xing, Yueyin Pan, Yuankai Shi, Yongqian Shu, Jifeng Feng, Wei Li, Lejie Cao, Lifeng Wang, Wei Gu, Yong Song, Puyuan Xing, Yutao Liu, Wen Gao, Jiuwei Cui, Nana Hu, Rutian Li, Hua Bao, Yang Shao, Jinming Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6168–6175.
https://doi.org/10.1158/1078-0432.CCR-20-2081
Published: 01 December 2020
View article titled, Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study
Open the PDF for Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study in another window
Includes: Supplementary data
Journal Articles

A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Yuqin Song, Jianqiu Wu, Xinchuan Chen, Tongyu Lin, Junning Cao, Yanyan Liu, Yaozhong Zhao, Jie Jin, Haiwen Huang, Jianda Hu, Jun Luo, Liling Zhang, Hongwei Xue, Qingyuan Zhang, Weiwei Wang, Chunxia Chen, Jifeng Feng, Jun Zhu
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7363–7369.
https://doi.org/10.1158/1078-0432.CCR-19-1680
Published: 13 December 2019
View article titled, A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
Open the PDF for A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma in another window
Includes: Supplementary data